Company Information Brief

Company Mission Statement
At Dr. Park, our mission is to revolutionize the accessibility and efficiency of
Cell and Gene Therapy (CGT) new drugs. We are committed to maximizing the
production efficiency and capacity of viral vectors, ensuring top-tier quality control
to make these advanced therapies available to more people.
Our state-of-the-art Phase 1 plant, set to be completed in March 2025, will
feature world-leading facilities with a production capacity of 6000L per batch. By
the end of 2025, we aim to achieve the highest level of cGMP certification,
underscoring our commitment to quality and excellence.
Founded solely by Dr. Park Yongho, without external investments, our vision is
driven by the founder’s dedication to making CGT new drugs a mainstream
treatment option. Through our cutting-edge production capabilities, stringent
quality controls, and agile organizational structure, we strive to lead the next
generation CGT new drug market as a premier CDMO company.
Overview
At Dr. Park, we are emerging leaders in the viral vector CDMO (Contract Development and Manufacturing Organization) industry, known for our unparalleled production capacity and commitment to quality. Specializing in AAV (Adeno-Associated Virus) related products, we boast the world’s largest production capacity for viral vectors, with an impressive 6,000 liters per batch and the ability to complete 26 batches per year. We can increase our production capability up to 10,000 liters per batch if there is a client’s request immediately, showcasing our flexibility and commitment to meeting client demands.
Services
We provide:
- • Small to large-scale production and refining services for viruses at competitive prices.
- • State-of-the-art quality control and examination facilities to ensure the highest standards of safety and efficacy.
Technology and Facilities
Dr. Park’s latest process technology has been continuously improved and is provided to customers in collaboration with various companies involved in vaccine production and development. Our advanced equipment includes :
Upstream Equipment:
- • 1000 Liter SUB x 5EA (Thermofisher Hyperforma)
- • 500 Liter SUB x 1EA
- • 250 Liter SUB x 1EA (Thermofisher Hyperforma)
- • 50 Liter SUB x 1EA (Thermofisher Dynadrive)
- • ACFM (Automated Cell Factory Machine) x 1EA
- • ACFM Incubator
- • Thermofisher Nunc Cell Factory Incubator x 1EA
- • 50 Liter Rocker Incubator (Thermofisher)
- • QUANTUM Bioreactor (3 liters)
- • Single Use Mixer
Downstream Equipment:
Our customized 800 LPM TFF equipment is the largest and most advanced globally, setting new standards in the industry.
- • FPLC 10 LPM x 1EA
- • TFF 800 LPM x 1EA
- • TFF 200 LPM x 1EA
- • TFF 20 LPM x 1EA
- • AKTA PILOT 600 x 2EA
- • AKTA FLUX x 1EA
Midstream Equipment:
- • Dynaspin (Thermofisher)
Buffer & Media Preparation:
- • 1000 Liter Mixer
- • 200 Liter Mixer
GMP Plasmid Production:
- • 700L x 2EA
- • 1400 Liter Fermenter
Our facility is on track to complete all construction and pre-operational tests by March 2025, with the goal of obtaining cGMP certification by the end of 2025. With a production lead time of just two weeks, Dr. Park is committed to delivering timely and efficient solutions to meet your needs.
Production Platforms
We are building a platform for large-scale GMP manufacturing and production technology for various viruses, including Adenovirus and Lentivirus. Our virus production utilizes the Cell Factory system for both adherent and suspension HEK 293 cells or single-use bioreactors in serum-free conditions for suspension HEK293 and CHO cells.
GMP Plasmid Manufacturing
Plasmids are small circular DNA structures containing DNA fragments, widely used in
genetic engineering and gene delivery (e.g., gene therapy, vaccine production). As experts
in plasmid amplification, we adhere to GMP (Good Manufacturing Practice) standards,
ensuring the effective minimization of risks during production that cannot be eliminated
even after final product testing.
At Dr. Park, we apply these principles to plasmid production, guaranteeing the provision of
safe and effective plasmid products. Our cutting-edge GMP facilities, developed through
continuous research and development, position us at the forefront of industry trends. Our
exceptional performance spans applications in research laboratories, pharmaceutical
development, and plant genetic engineering. We deliver reliable and effective results
swiftly, ensuring our services are recognized internationally. Our annual plasmid production
capability, adhering to GMP standards, is 3.9 kg per year.
Protein Bioproduction
Dr. Park has successfully produced many proteins based on more than 10 years of diverse experience in customized protein production and is a leader in recombinant protein production that is difficult for expression. We provide large amounts of protein expression and purification services from low doses using Dr. Park’s own system at a low price. Dr. Park provides the most advanced high-throughput protein production platform based on the knowledge and know-how of the best protein production experts. Therefore, Dr. Park builds all systems to meet or surpass the customer’s requirements through a high-level production platform.
Partnership with Dr. Park
Leverage our expertise in products, advanced facilities, and dedicated service to accelerate your path to market with confidence.
Contact Information
- • Address: 555, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do, South Korea
- • Tel: +82-31-734-0077
- • Fax: +82-2-6455-7512
- • C.P: +82-10-8864-7512
- • E-mail: president@drpark-cdmo.com
- • WhatsApp ID: +821088647512